Cyclerion Therapeutics Inc(CYCN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.68 | Insider Own | 64.01% | Shs Outstand | 4.3M | Perf Week | -8.7% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.7M | Perf Month | -5.88% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 35.53% | Short Float | 3.12% | Perf Quarter | 11.63% |
| Income | -0.01B | P/S | 8.28 | EPS this Y | - | Inst Trans | 48.6% | Short Ratio | 1.33 | Perf Half Y | 125.5% |
| Sales | 0.00B | P/B | 2.81 | EPS next 5Y | - | ROA | -82.29% | Short Interest | 0.05M | Perf YTD | 164.57% |
| Book/sh | 1.2 | P/C | 11.32 | EPS past 3/5Y | 62.04% 53.53% | ROE | -98.22% | 52W High | -60.38% ($8.48) | Perf Year | 48.67% |
| Cash/sh | 0.3 | P/FCF | - | Sales past 3/5Y | 91.14% -2.01% | ROIC | -131.85% | 52W Low | 227.29% ($1.03) | Perf 3Y | -5.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -126.25% | Gross Margin | - | Volatility(W/M) | 13.73% 11.18% | Perf 5Y | -94.6% |
| Dividend TTM | - | EV/Sales | 7.55 | Sales Y/Y TTM | -12.6% | Oper. Margin | -359.16% | ATR (14) | 0.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.82 | EPS Q/Q | -291.28% | Profit Margin | -353% | RSI (14) | 41.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.82 | Sales Q/Q | -100% | SMA20 | -16.24% ($4.01) | Beta | 1.75 | Target Price | $8 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/03/25 | SMA50 | -10.36% ($3.75) | Rel Volume | 11.08 | Prev Close | $4.25 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 31.23% ($2.56) | Avg Volume(3M) | 0.04M | Price | $3.36 |
| IPO | 2019/3/18 | Option/Short | No/Yes | Trades | 2181 | Volume | 435,610 | Change | -20.94% |
🧠 Cyclerion Therapeutics is a clinical-stage biotech specializing in central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulators. Its lead asset, zagociguat (formerly CY6463), has been building a clinical data set in mitochondrial diseases (such as MELAS), vascular Alzheimer's disease (ADv), and cognitive impairment associated with schizophrenia (CIAS), and has secured Orphan Drug designation from the FDA for mitochondrial diseases.
Over the past 1 year, roughly in the middle
60% below its 1-year high.
Traded more than usual. That is 1108% of its average volume.
CYCN has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $828. Peers typically go for $948.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.6%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #478 of 598 in the industry
Based on market cap of $16M.
NEUP#476 Neuphoria Therapeutics Inc $16M PER - 
KYNB#477 Kyntra Bio Inc $16M PER 0.1 CYCN#478 Cyclerion Therapeutics Inc $16M PER - 
ABOS#478 Acumen Pharmaceuticals Inc $16M PER - 
PLUR#479 Pluri Inc $16M PER - 
FAQ
What kind of company is CYCN?
CYCN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CYCN?
The market cap of CYCN is approximately $16M, ranking 5,382 within its sector.
What is the 52-week high and low for CYCN?
CYCN has recorded a 52-week high of $8.48 and a low of $1.03.
